Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

Express Scripts aims to ensure that patients directly benefit from its negotiations with drug manufacturers. The new approach will protect patients from paying inflated list prices for medications, ...

The National Community Pharmacists Association has joined a class action lawsuit against GoodRx, as well as CVS Caremark, ...

Bloomfield-based Cigna announced this week a new initiative that aims to reduce out-of-pocket prescription-drug costs and ...

Fresh off underperforming Wall Street’s expectations in the fourth quarter, Cigna said it would work to lower costs for its ...

Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while ...

Cigna executives kicked off Thursday’s earnings call by responding to pharmacy benefit manager critics with a number of reforms.

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

A safety net health care provider has won a $10.3 million interim arbitration judgment against Eagan-based Prime Therapeutics over price-fixing allegations between the local pharmacy benefits manager ...

Sycamore Partners has been speaking with private credit firms about debt financing for a potential deal, despite an earlier report that takeover talks had stalled.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.